Skip to main content

Milestone 6.D

Initiate drug discovery efforts to develop novel therapeutic agents against at least 6 novel therapeutic targets (a minimum of three targets for presymptomatic and early stage disease and a minimum of three for advanced disease).

Success Criteria

Complete preclinical development, through IND filing, of at least 12 therapeutics agents against at least 3 novel targets (at least one novel target should be for presymptomatic disease).

Invest in the expansion of therapeutic modalities inlcuding natural products, gene therapy, antisense oligonucleotides, cell therapy, etc...

Time Required

2017 to 2023

Research Implementation Area

Drug Development - Novel Targets

CADRO Category

C. Translational Research and Clinical Intervention

Activities, Funding Initiatives, and Resources

NIH Accelerating Medicines Partnership-AD – Target Discovery and Preclinical Va…
NIH RFA-AG-15-018: Immune and Inflammatory Mechanisms in Alzheimer’s Disease (R…
NIH RFA-AG-15-010: Interdisciplinary Research to Understand the Vascular Contri…
NIH RFA-AG-14-002: Optogenetic Tools for the Study of Neural Systems in Aging a…
NIH RFA-AG-13-013: Interdisciplinary Approach to Identification and Validation …
NIH PA-16-091: Small Business Alzheimer's Disease Research (R43/R44)
NIH PA-16-092: Small Business Alzheimer's Disease Research (R41/R42)
NIH PAR-18-183: T1 Translational Research on Aging: Small Business Innovation A…
NIH PAR-18-175: Pilot Clinical Trials for the Spectrum of Alzheimer’s Disease a…
NIH PAR-18-513: Alzheimer's Clinical Trials Consortium (ACTC) Clinical Trials (…
NIH PAS-18-188: Advancing Research on Alzheimer's Disease (AD) and Alzheimer's-…
NIH PAR 18-505: Assay Development to Accelerate Target Identification and Thera…
NIH PAR 17-336: Chemical Probes for Novel Brain Targets
NIH PAR 18-820: Alzheimer’ Disease Drug Development
NIH PAR 18-546: Blueprint Neurotherapeutics
NIH PAR 18-541: Blueprint Neurotherapeutics